O’Connell C et al. – The series highlights the potential malignant risk of anti–TNF theraphy to a general medical audience.Methods
- Retrospective review of patients over an 18–month period who were referred to a multidisciplinary lung cancer service.
- Three patients who underwent recent anti–TNF therapies and presented with solid organ tumours.
- All had significant additional risks for cancer including smoking and family history and active connective tissue diseases with a past history of immunosuppressive therapies.